0.68 - 0.75
0.33 - 0.86
18.34M / 4.66M (Avg.)
34.50 | 0.02
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-13.40%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-37.16%
Both firms have negative gross profit growth. Martin Whitman would question the sector’s viability or cyclical slump.
-160.18%
Negative EBIT growth while 3606.HK is at 33.57%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-160.18%
Negative operating income growth while 3606.HK is at 50.11%. Joel Greenblatt would press for urgent turnaround measures.
-2470.86%
Negative net income growth while 3606.HK stands at 73.41%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-2340.00%
Negative EPS growth while 3606.HK is at 75.76%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-2611.11%
Negative diluted EPS growth while 3606.HK is at 72.73%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
8.64%
Slight or no buybacks while 3606.HK is reducing shares. John Neff might see a missed opportunity if the company’s stock is cheap.
-0.01%
Reduced diluted shares while 3606.HK is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-3.94%
Dividend reduction while 3606.HK stands at 2797.65%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
6.72%
OCF growth at 50-75% of 3606.HK's 12.64%. Martin Whitman would question if the firm lags in monetizing sales effectively.
8.02%
Positive FCF growth while 3606.HK is negative. John Neff would see a strong competitive edge in net cash generation.
-50.96%
Negative 10Y revenue/share CAGR while 3606.HK stands at 83.04%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
-59.12%
Negative 5Y CAGR while 3606.HK stands at 34.20%. Joel Greenblatt would push for a turnaround plan or reevaluation of the company’s product line.
-37.20%
Negative 3Y CAGR while 3606.HK stands at 14.07%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
-369.96%
Negative 10Y OCF/share CAGR while 3606.HK stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
8.30%
Below 50% of 3606.HK's 115.88%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
36.01%
3Y OCF/share CAGR above 1.5x 3606.HK's 9.19%. David Dodd would confirm if the firm is quickly gaining an operational edge over the competitor.
-175.70%
Negative 10Y net income/share CAGR while 3606.HK is at 194.69%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-159.50%
Negative 5Y net income/share CAGR while 3606.HK is 107.79%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-1528.07%
Negative 3Y CAGR while 3606.HK is 61.37%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
63.91%
Below 50% of 3606.HK's 224.88%. Michael Burry would suspect poor capital allocation or persistent net losses eroding long-term equity build-up.
-16.92%
Negative 5Y equity/share growth while 3606.HK is at 45.21%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.
-22.64%
Negative 3Y equity/share growth while 3606.HK is at 28.25%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
64.08%
Below 50% of 3606.HK's 2810.30%. Michael Burry might see weaker long-term distribution growth, raising questions about the firm's capital allocation.
-75.82%
Negative 5Y dividend/share CAGR while 3606.HK stands at 30.15%. Joel Greenblatt sees a weaker commitment to dividends vs. a competitor that might be growing them.
-33.71%
Negative near-term dividend growth while 3606.HK invests at 29.16%. Joel Greenblatt sees a weaker short-term distribution policy unless justified by strategic spending.
1.80%
Our AR growth while 3606.HK is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.
-26.93%
Inventory is declining while 3606.HK stands at 7.78%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
11.24%
Asset growth above 1.5x 3606.HK's 2.89%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
-11.94%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
77.55%
Debt growth far above 3606.HK's 10.74%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-34.23%
Our R&D shrinks while 3606.HK invests at 5.61%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-10.18%
Both reduce SG&A yoy. Martin Whitman sees a cost war or cyclical slowdown forcing overhead cuts.